AVITA Medical (RCEL) to Release Quarterly Earnings on Monday

AVITA Medical (NASDAQ:RCEL) is scheduled to be announcing its earnings results after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

AVITA Medical (NASDAQ:RCEL) last posted its earnings results on Thursday, February 22nd. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. The firm had revenue of $14.20 million during the quarter, compared to analysts’ expectations of $14.10 million. AVITA Medical had a negative net margin of 70.56% and a negative return on equity of 54.80%. On average, analysts expect AVITA Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AVITA Medical Stock Performance

RCEL opened at $8.75 on Monday. The company has a current ratio of 7.88, a quick ratio of 7.46 and a debt-to-equity ratio of 0.81. The business’s 50 day moving average is $13.84 and its 200-day moving average is $13.54. The stock has a market cap of $225.75 million, a PE ratio of -6.25 and a beta of 1.42. AVITA Medical has a twelve month low of $8.01 and a twelve month high of $21.70.

Wall Street Analyst Weigh In

RCEL has been the subject of a number of analyst reports. Piper Sandler reiterated an “overweight” rating and set a $21.00 price target (up previously from $19.00) on shares of AVITA Medical in a research report on Friday, February 23rd. Cantor Fitzgerald upped their price objective on shares of AVITA Medical from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Finally, BTIG Research cut shares of AVITA Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $27.80.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.